Boehringer pharma head to step down

Aug. 27, 2019

Boehringer Ingelheim recently announced changes in its board of managing directors, beginning with Allan Hillgrove, member of the board responsible for the human pharma and the biopharma business, stepping down from the board and retire at the end of this year after 37 years with the company.

Hillgrove joined Boehringer Ingelheim in 1982 in Australia as a sales representative in animal health.In 2013, the shareholders appointed him to the board of managing directors as head of the human pharma business. Responsibility for the biopharma business was added in 2018.

Carine Brouillon has been named as Hillgrove's successor. Brouillon joined Boehringer in 2018 as the head of therapeutic areas for prescription medicines.

Also at the end of this year, Joachim Hasenmaier will retire and step down from the board as head of the animal health business. Hasenmaier joined Boehringer Ingelheim in 2001 as head of the animal health division.

Jean Scheftsik de Szolnok has been appointed to the board as new head of the animal health business unit, effective January 1, 2020. 

According to Boehringer, to keep up with trends the responsibility for the overall people strategy will move under the leadership of the chairman of the board of managing directors, effective October 1. At the same time, new technologies and digital transformation have moved many tasks of enabling corporate functions closer together, which has caused the company to shift some HR activities to the board division finance.

In response, Andreas Neumann has decided to step down from the board of managing directors at the end of September and will leave the corporation after more than eight years of work.

Read the full Boehringer Ingelheim release